Literature DB >> 16353916

Recommended reading in population pharmacokinetic pharmacodynamics.

Peter L Bonate1.   

Abstract

Developing the skills or expertise to create useful population pharmacokinetic-pharmacodynamic models can be a daunting task-the level of mathematical and statistical complexity is such that newcomers to the field are frequently overwhelmed. A good place to start in learning the field is to read articles in the literature. However, the number of articles dealing with population pharmacokinetic pharmacodynamics is exponentially increasing on a yearly basis, so choosing which articles to read can be difficult. The purpose of this review is to provide a recommended reading list for newcomers to the field. The list was chosen based on perceived impact of the article in the field, the quality of the article, or to highlight some important detail contained within the article. After reading the articles in the list, it is believed that the reader will have a broad overview of the field and have a sound foundation for more-detailed reading of the literature.

Mesh:

Year:  2005        PMID: 16353916      PMCID: PMC2750974          DOI: 10.1208/aapsj070237

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  33 in total

1.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

2.  Design and power of a population pharmacokinetic study.

Authors:  P I Lee
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

3.  Model appropriateness and population pharmacokinetic modeling.

Authors:  Ene I Ette; Paul J Williams; Yong Ho Kim; James R Lane; Mei-Jen Liu; Edmund V Capparelli
Journal:  J Clin Pharmacol       Date:  2003-06       Impact factor: 3.126

4.  Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; E Niclas Jonsson; Mats O Karlsson
Journal:  AAPS PharmSci       Date:  2002

5.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

6.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

7.  Population pharmacokinetics of ciprofloxacin in pediatric patients.

Authors:  Prabhu Rajagopalan; Marc R Gastonguay
Journal:  J Clin Pharmacol       Date:  2003-07       Impact factor: 3.126

8.  Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.

Authors:  René Bruno; Pascale Baille; Sylvie Retout; Nicole Vivier; Christine Veyrat-Follet; Ger-Jan Sanderink; Richard Becker; Elliott M Antman
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

9.  Prospective evaluation of a D-optimal designed population pharmacokinetic study.

Authors:  Bruce Green; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-04       Impact factor: 2.745

10.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
View more
  20 in total

Review 1.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 2.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

Authors:  Stephen B Duffull; Daniel F B Wright; Helen R Winter
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

3.  Utility of a Bayesian Mathematical Model to Predict the Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins.

Authors:  Steven Kathman; Theingi M Thway; Lei Zhou; Stephanie Lee; Steven Yu; Mark Ma; Naren Chirmule; Vibha Jawa
Journal:  AAPS J       Date:  2016-01-19       Impact factor: 4.009

Review 4.  Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.

Authors:  C Dartois; K Brendel; E Comets; C M Laffont; C Laveille; B Tranchand; F Mentré; A Lemenuel-Diot; P Girard
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

Review 5.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera.

Authors:  Anouk E Muller; Paul M Oostvogel; Joost DeJongh; Johan W Mouton; Eric A P Steegers; P Joep Dörr; Meindert Danhof; Rob A Voskuyl
Journal:  Antimicrob Agents Chemother       Date:  2009-01-21       Impact factor: 5.191

Review 7.  Understanding the time course of pharmacological effect: a PKPD approach.

Authors:  Daniel F B Wright; Helen R Winter; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

8.  Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.

Authors:  Patanjali Ravva; Marc R Gastonguay; Hélène M Faessel; Theodore C Lee; Raymond Niaura
Journal:  Nicotine Tob Res       Date:  2014-08-21       Impact factor: 4.244

9.  The parameter Houlihan: A solution to high-throughput identifiability indeterminacy for brutally ill-posed problems.

Authors:  David J Albers; Matthew E Levine; Lena Mamykina; George Hripcsak
Journal:  Math Biosci       Date:  2019-08-24       Impact factor: 2.144

10.  Pharmacokinetics of clindamycin in pregnant women in the peripartum period.

Authors:  Anouk E Muller; Johan W Mouton; Paul M Oostvogel; P Joep Dörr; Rob A Voskuyl; Joost DeJongh; Eric A P Steegers; Meindert Danhof
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.